M V Taranova - JoVE Visualize

Showing results (21-30 of 25) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 25 results.

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk|January 4, 2018

[Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance]L Y Milovanova, N A Mukhin, L V Kozlovskaya, et al.

Terapevticheskii Arkhiv|December 6, 2022

[Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in patients with chronic kidney disease]M V Taranova, L Y Milovanova, L V Kozlovskaya Lysenko, et al.

Terapevticheskii Arkhiv|December 6, 2022

[Low protein diet with essential amino acids ketoanalogues combination can affect serum FGF-23 and Klotho levels in chronic kidney disease 3b-4 stages patients: randomized pilot study]L Y Milovanova, L V Kozlovskaya Lysenko, T V Androsova, et al.

Scientific Reports|May 22, 2026

Mast cell-driven remodeling of pulmonary immune and stromal landscapes in COVID-19D A Atiakshin, O A Burgasova, A A Kostin, et al.

Terapevticheskii Arkhiv|July 4, 2013

[Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases]S V Moiseev, P I Novikov, E N Semenkova, et al.

Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 25 results.

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk|January 4, 2018

[Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance]L Y Milovanova, N A Mukhin, L V Kozlovskaya, et al.

Terapevticheskii Arkhiv|December 6, 2022

[Serum troponin-I as a marker of fibroblast growth factor-23 (FGF-23) cardiotoxic effect, in patients with chronic kidney disease]M V Taranova, L Y Milovanova, L V Kozlovskaya Lysenko, et al.

Terapevticheskii Arkhiv|December 6, 2022

[Low protein diet with essential amino acids ketoanalogues combination can affect serum FGF-23 and Klotho levels in chronic kidney disease 3b-4 stages patients: randomized pilot study]L Y Milovanova, L V Kozlovskaya Lysenko, T V Androsova, et al.

Scientific Reports|May 22, 2026

Mast cell-driven remodeling of pulmonary immune and stromal landscapes in COVID-19D A Atiakshin, O A Burgasova, A A Kostin, et al.

Terapevticheskii Arkhiv|July 4, 2013

[Severe adverse events from treatment with genetically engineered biological agents in patients with rheumatic diseases]S V Moiseev, P I Novikov, E N Semenkova, et al.

Pageof 3